Abeona Therapeutics Reports 2025 Financial Results and Operational Milestones

Key Highlights for Investors

• First Commercial Treatment of ZEVASKYN® Completed: Abeona successfully completed its first commercial patient treatment with ZEVASKYN® (prademagene zamikeracel) in December 2025, marking a pivotal milestone for the company’s transition to commercial-stage operations.
• ZEVASKYN Launch Momentum: Commercial activities for ZEVASKYN began in Q4 2025, paused for a mandatory annual manufacturing shutdown, and resumed in late January 2026. Multiple patient biopsies have since been collected, with additional treatments expected imminently. The company anticipates that initial positive patient experiences will catalyze increased demand across the RDEB community.
• Expansion of Qualified Treatment Center (QTC) Network: In December, Abeona activated its fourth QTC at The University of Texas Medical Branch (UTMB), a major academic medical center specializing in complex skin disease and wound care. This expansion broadens patient access across Texas and the Gulf Coast region.
• Financial Position:
  • Cash, Cash Equivalents, and Short-term Investments: \$191.4 million as of December 31, 2025, providing strong liquidity for ongoing expansion and commercialization.
  • Total Revenue: \$5.8 million for 2025, including \$2.4 million in net product revenue (from Medicaid coverage for the first patient) and \$3.4 million in license and milestone revenues.
  • Cost of Sales: \$1.5 million, primarily reflecting the first ZEVASKYN patient and costs from an August batch not released due to FDA-mandated assay challenges.
  • R&D Expenses: \$26.8 million, down \$7.6 million from 2024, as production costs were capitalized post-FDA approval in April 2025.
  • SG&A Expenses: \$65.0 million, up \$35.1 million, reflecting commercial build-out including personnel, stock-based compensation, and direct commercialization costs.
  • Rare Pediatric Disease Priority Review Voucher Sale: Abeona sold its PRV for \$155.0 million in June 2025, realizing a net gain of \$152.4 million, significantly boosting its cash position.
  • Net Income: \$71.2 million in 2025 (\$1.34 per basic share, \$1.01 per diluted share), a dramatic turnaround from a net loss of \$(63.7) million in 2024.

Operational Progress & Commercialization Strategy

• Manufacturing & Workflow Optimization: After optimizing a release assay in 2025 and overcoming technical challenges, Abeona has resumed manufacturing with a steady cadence of biopsies and treatments. The company is focused on scaling up patient throughput and streamlining referral-to-treatment timelines.
• Market Demand Drivers: Positive early treatment experiences are expected to drive further demand for ZEVASKYN, especially as the RDEB (recessive dystrophic epidermolysis bullosa) community shares success stories. The company expects average net revenues to normalize as payer mix shifts to include commercially insured patients.
• Infrastructure: Abeona’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio is the site for ZEVASKYN commercial production.

Balance Sheet Details

• Total Assets: \$219.6 million as of December 31, 2025, up from \$108.9 million in 2024.
• Total Liabilities: \$60.4 million, down from \$64.9 million the prior year.
• Total Stockholders’ Equity: \$159.2 million, a major increase from \$44.0 million in 2024.
• Share Count: Common shares outstanding increased to 55.0 million from 45.6 million in 2024.

Forward-Looking Statements & Risks

• Abeona’s outlook includes risks related to commercial scaling, manufacturing, regulatory approvals, and market adoption. Continued successful commercialization of ZEVASKYN and expansion of its QTC network are key to future growth. Investors should monitor FDA regulatory interactions, manufacturing performance, payer mix evolution, and competitive landscape.

Potential Share Price Sensitivity

• Major Positive Factors:
  • Successful launch and scaling of ZEVASKYN, the first approved autologous cell-based gene therapy for RDEB, is likely to drive significant investor interest.
  • Sale of the PRV for \$155M is a one-time cash windfall, strengthening financial flexibility and reducing funding risk.
  • Turnaround to profitability and strong balance sheet may positively impact valuation multiples.
  • Expansion of treatment centers and early patient success stories could accelerate adoption and revenue growth.
• Risks & Watchpoints:
  • Scaling manufacturing and ensuring consistent batch releases remain operational risks.
  • Market adoption will depend on payer coverage, referral timelines, and competitive therapies.
  • The sustainability of positive financials depends on successful commercialization and market uptake.

Upcoming Events

Abeona will host a conference call on March 17, 2026, at 8:30 a.m. ET to discuss financial results and corporate progress. Investors may join via phone or webcast for further details and Q&A.

About Abeona Therapeutics

Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on cell and gene therapies for severe diseases. Its flagship product, ZEVASKYN®, treats wounds in adult and pediatric patients with RDEB. The company also develops AAV-based gene therapies for ophthalmic diseases and novel next-generation AAV capsids for a variety of devastating diseases.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks and uncertainties as outlined in Abeona’s filings with the SEC. Investors should perform their own due diligence before making investment decisions.

View ABEONA THERAPEUTICS INC. Historical chart here